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Abstract 
BACKGROUND: Coronary artery disease (CAD) is the leading cause of mortality and morbidity in patients with 
diabetes (DM).  
AIM: Тhe aim of our study was to analyse the ability of pharmacological SE to risk stratify patients with DM using 
qualitative and quantitative assessment of LV function. 
METHODS: We prospectively assessed 105 consecutive patients (58.7 ± 9.5 y, 39 male) with known or 
suspected CAD who underwent dipyridamole or dobutamine SE. 
RESULTS: Change of systolic LV function at maximal SE was less pronounced in patients with DM, while 
parameters of the diastolic function and its change with stress were almost insignificant. WMSI in comparison to 
GLS% didn’t make a difference in SE outcome regarding DM presence. WMSI was almost unchanged at maximal 
stress in diabetic patients. Conversely, GLS% showed significant worsening at maximal stress in diabetic patients. 
However, only WMSI at maximal stress along with DM presence appeared as independent predictors of the 
presence of new and worsening CAD during SE. Longitudinal strain assessed using speckle tracking during 
pharmacological stress echocardiography was superior to conventional echocardiography expressed by wall 
motion analysis in making a difference regarding DM presence.  
CONCLUSION: We confirmed the usefulness of stress echocardiography using qualitative and/or quantitative 
parameters in the detection of CAD in patients with DM. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Coronary artery disease (CAD) is the leading 
cause of mortality and morbidity in patients with 
diabetes. Approximately one-half of deaths are 
attributed to CAD in diabetic patients [1], whose risk of 
myocardial infarction or cardiac death is two-to four-
fold as great compared with nondiabetic patients [2] 
[3]. Moreover, cardiac events are as frequent in 
diabetic patients without evidence of CAD as in 
nondiabetic patients with known CAD [4]
.
 The 
increased risk associated with diabetes calls for 
effective prevention [5], [6], [7], [8] and risk 
stratification strategies to optimise therapeutic 
interventions [9]. Exercise testing is of limited value in 
the diabetic population because exercise capacity is 
often impaired by peripheral vascular [10] or 
neuropathic disease [11]. Furthermore, test specificity 
is less than ideal [12] because of the high prevalence 
of hypertension [13] and microvascular disease
14
. 
Stress echocardiography (SE) represents an 
established diagnostic [15] and prognostic modality 
[16], [17], [18], [19] in diabetic patients. However, it is 
still undefined whether it retains the same prognostic 
value in diabetic and nondiabetic patients.  
Тhe aim of our study was to analyse the 
ability of pharmacological (dobutamine or 
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dipyridamole) stress echocardiography (SE) to risk 
stratify patients with DM using qualitative and/or 
quantitative assessment of LV function.  
 
 
Methods  
 
We prospectively assessed 105 consecutive 
patients, with a mean age of 58.7 ± 9.5 years, who 
underwent dipyridamole or dobutamine stress 
echocardiography between January 2016 and May 
2018 in a University Clinic of cardiology in Skopje. 
Before the study, patients’ demographic 
characteristics were obtained, and patients were 
questioned about the presence of atherosclerotic risk 
factors, previous CAD and angioplasty. Subjects were 
classified as having diabetes when treated for insulin-
dependent or non-insulin-dependent diabetes or 
having elevated fasting glucose levels according to 
issued up-to-date standards from professional 
organisations.  
The indications for the exam was a referral 
from a physician according to the complaints of the 
participating patient or was a result of inconclusive 
results of treadmill stress testing. Written informed 
consent to undergo stress testing and to participate in 
the study was obtained from each patient.  
Echocardiographic examination was 
performed using GE, Vivid 7 with a recording of the 
views and later analysing on the machine itself or 
acoustic-tracking software (Echo Pac, GE). All 
measurements were performed according to 
guidelines suggested by professional 
echocardiographic societies [20], [21].  
An accelerated high-dose dipyridamole 
protocol was used for all patients. Dipyridamole was 
infused intravenously at a dose of 0.84 mg/kg body 
weight over 6 min. Aminophylline (up to 240 mg) was 
routinely administered to patients 5 min after the end 
of the test or immediately if there were obvious clinical 
and/or ECG signs of ischemia. Dobutamine was 
administered intravenously beginning at a dose of 10 
g/kg body weight and minute and increased in steps 
every 3 minutes to 20, 30, and 40 g/kg.  
Two-dimensional echocardiography, blood 
pressure measurements and 12-lead 
electrocardiography (ECG) were used for continuous 
monitoring during the test and the recovery phase. 
Echocardiographic images were semi-quantitatively 
assessed using 17 segments, and wall motion score 
index (WMSI) was derived by dividing the sum of 
individual segment scores by the number of 
interpretable segments. Ischemia was defined as 
stress-induced new and/or worsening of pre-existing 
wall motion abnormality, or biphasic response (i.e. 
low-dose improvement followed by high-dose 
deterioration) [22], [23]. 
Global longitudinal strain (GLS%) for the LV 
was automatically provided as the average value of 
the regional peak systolic longitudinal strain of the 
three apical views by the software [24], [25], [26]. The 
images for analysis were obtained out of stress-echo 
protocol. All images were recorded with a high frame 
rate (> 50 frames/s). The LV was divided into 17 
segments, and each segment was analysed 
individually. Only myocardial segments considered to 
be of adequate quality by both the automatic system 
and the operator were included in the analysis. All 
examinations were assessed by the same 
cardiologist. 
Sixty-one patients underwent coronary 
angiography within a few days of the stress 
echocardiography tests. Angiographic assessments 
involved presence and quantification of stenosis 
severity as well as the calculation of Syntax score. 
The study protocol was approved by the 
Medical Ethics Committee of Medical School, 
University “St. Cyril & Methodius), Skopje. 
Categorical parameters were summarised as 
percentages and continuous parameters as mean ± 
SD. Comparisons between the two groups with and 
without DM was performed using the Mann-Whitney 
nonparametric test for continuous parameters and 
Pearson’s chi-square test for categorical parameters. 
Comparisons between the two groups before and 
after stress were performed using Wilcoxon Signed 
Rank test. Assessment of correlation of various 
echocardiographic parameters was done using 
Pearson’s correlation analysis. Multiple logistic 
regression analysis was performed in stepwise order 
to determine independent predictors among clinical 
and echocardiographic covariates of the positive 
stress echocardiographic result. All data analysis was 
performed using SPSS version 25.0 (IBM SPSS, Inc., 
Chicago, Illinois) and p-value ≤ 0.05 was considered 
significant. 
 
 
 
Results 
 
Out of 105 patients who underwent SE, DM 
was present in 36 (34.3%); 22/61,2% were taking oral 
antidiabetic drugs, and 14/38.9% were using insulin to 
control diabetes. In comparison to patients without 
DM, those with DM were older (p = 0.0001), with 
higher BMI (p = 0.034), less frequently were current 
smokers (p = 0.033), but more frequently had a history 
of hypertension (p = 0.013) and insignificantly higher 
percentage of the history of CAD  
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Table 1: Basal and functional characteristics, symptoms and 
ECG changes of patients divided according to the DM 
presence 
Parameter 
With DM 
N = 36 
Without DM 
N = 69 
p 
Age (y) 63.1 ± 6.7 56.4 ± 9.9 0.0001 
Gender (m/f %) 36.1/63.9 37.7/62.3 0.874 
BMI  (kg/m
2
) 30.4 ± 4.6 28.3 ± 5.1 0.034 
Current smoking (n/%) 9/25.0 32/46.4 0.033 
History of hypertension (n/%) 32/88.9 46/66.7 0.013 
History of dislipidemia (n/%) 25/69.4 48/69.6 0.580 
History of CAD (n/%) 15/41.7 19/27.5 0.142 
Beta-blocker therapy (n/%) 23/21.9 37/35.2 0.313 
Calcium channel blocker therapy 
(n/%) 
7/19.4 17/24.6 0.547 
Symptoms (n%) 7/19,4 14/20.3 0,918 
ECG changes  (n/%) 10/27.8 13/18.8 0,293 
Rhythm disorder (n/%) 4/11.1 6/8.7 0,689 
 BPs (mmHg) -1.2 ± 20.1 1.1 ± 17.4 0.525 
BPd (mmHg) 1.5 ± 10.3 2.2 ± 9.8 0.713 
HR rest (Imp/min) 79.5 ± 15.2 72.0 ± 11.2 0.005 
HR max (Imp/min) 105.9 ± 21.3 97.9 ± 18.1 0.048 
HR  (Imp/min) -26.4 ± 18.37 -25.8 ± 14.8 0.876 
DM = diabetes mellitus; BMI = body mass index, CAD = coronary artery disease; ECG = 
electrocardiogram; BP = blood pressure; s = systolic;d=diastolic; HR = heart rate; = 
change from rest to maximal dose of stressor; *p<0.05 for comparison between groups. 
 
Dobutamine or dipyridamole pharmacological 
protocol was applied in equal half’s of patients with 
DM, while those without DM receive more frequently 
dipyridamole protocol (p = 0.049). Although systolic 
blood pressure increase with SE in patients with DM 
while a decrease in patients without DM, there was no 
significant difference in change. With SE diastolic 
pressure decrease in both groups of patients without 
difference between them. Heart rate was significantly 
higher in patients with DM at rest as well as at 
maximal dose of the stressor (peak stress), but there 
was lack of significant difference in its change (delta) 
(Table 1).  
Comparison of systolic LV functional data 
during SE showed an insignificant increase of LV 
ejection fraction (LVEF) and significant increase of 
indexed systolic volume (SV/BSA), indexed cardiac 
output (CI) and early diastolic mitral annular tissue 
Doppler velocity (s’TDI) in both groups of patients 
(Table 2). Although the change (delta value) from rest 
to peak stress was less pronounced in patients with 
DM, the difference between groups was not significant 
for all values (Table 2). As for parameters of diastolic 
function, comparison of data showed insignificant 
increase of left atrial volume index (LAVI), significant 
increase of early diastolic mitral annular tissue 
Doppler velocity (e’TDI) and insignificant increase of 
value of LV filling pressure expressed as E/e’ratio in 
patients with DM without significant difference 
between respective delta values (Table 2). Value of 
transmitral flow parameters showed a significant 
decrease in patients with DM and only for deceleration 
time (DT) and isovolumetric relaxation time for 
patients without DM, whereas delta value was border 
significant only for DT mostly for diabetic patients. 
As for WMSI, besides it was insignificantly 
higher in diabetic patients at rest, it has been shown 
that the index was almost unchanged during stress in 
both groups of patients, whereas in diabetic patients 
GLS% showed worsening (more positive or 
decreased negative value) at maximal stress which 
was significantly different to those without DM who 
showed slight improvement (less positive or increased 
negative value) of GLS% (Table 3).  
Table 2: Comparison of systolic and diastolic parameters 
during SE in patients divided according to the DM presence 
Parameter With DM N = 36 Without DM N = 69 p** 
At rest Max stress At rest Max stress 
LVEF (%) 60.1 ± 8.7 60.4 ± 10.1 62.0 ± 8.2 63.7 ± 8.5 0.378 
p* 0.922 0.076 
SV/BSA (ml/m
2
) 41.8 ± 12.0 90.6 ± 21.6 43.5 ± 10.7 95.2 ± 25.0 0.486 
p* 0.0001 0.0001 
CI (L/min/m
2
) 3.4 ± 1.3 9.2 ± 2.7 3.0 ± 0.8 8.8 ± 2.9 0.896 
p* 0.0001 0.0001 
s’TVI (cm/s) 7.7 ± 1.4 9.1 ± 2.3 7.4 ± 1.0 8.6 ± 2.0 0.461 
p* 0.0001 0.0001 
LAVI (ml/m
2
) 19.5 ± 5.3 19.6 ± 5.6 18.3 ± 6.0 19.2 ± 7.0 0.756 
p* 0.753 0.156 
Е/А 0.9 ± 0.2 0.8 ± 0.2 1.0 ± 0.2 1.0 ± 0.3 0.318 
p* 0.033 0.504 
DT (ms) 195.0 ± 53.1 130.9 ± 44.3 206.0 ± 47.1 167.6 ± 52.4 0.051 
p* 0.0001 0.0001 
IVRT (ms) 83.3 ± 16.3 63.1 ± 11.2 85.4 ± 15.1 65.4 ± 8.6 0.787 
p* 0.0001 0.0001 
е’ TDI average 9.3 ± 2.2 10.1 ± 2.4 9.6 ± 1.9 10.7 ± 2.4 0.919 
p* 0.009 0.0001 
E/e’ average 9.5±2.8 9.6±2.7 8.9±2.4 8.9±2.6 0.973 
p* 0.912 0.754 
LVEF = left ventricular ejection fraction; SVI = systolic volume indexed to BSA; CI = 
cardiac output indexed to BSA; s’TDI = peak systolic mitral annular velocity by TDI; LAVI = 
maximum left atrial volume indexed to BSA; E velocity = early mitral inflow velocity; A 
velocity = late mitral inflow velocity; DT = deceleration time; IVRT = isovolumetric 
relaxation time; e’ TDI = early diastolic mitral annular tissue Doppler velocity; *p < 0.05 for 
comparison between groups; **p = comparison of delta values between two groups. 
 
However, the significant difference of GLS% 
delta values between diabetic and non-diabetic 
patients was not confirmed (Table 3). About the 
number of segments with longitudinal LV strain < 12% 
the outcome of stress was the same as for GLS%. 
Thus there was no a significant difference in stress 
outcome in diabetic patients vs non-diabetic (Table 3). 
Also, the percentage of positive results according to 
the worsening of WMSI and/or GLS% during SE were 
insignificantly more frequent in diabetic patients 
(Table 3). 
Table 3: Comparison of wall motion score index and global 
longitudinal LV strain values during SE in patients divided 
according to the DM presence 
Parameter With DM 
N = 36 
Without DM 
N = 69 
p 
WMSI at rest 1.12 ± 0.14 1.05 ± 0.09 0.337 
WMSI at peak stress 1.10 ± 0.15 1.07 ± 0.13 0.579 
WMSI 0.01 ± 0.17 -0.01 ± 0.12 0.126 
GLS (%) at rest -15.0 ± 3.7 -16.6 ± 5.0 0.905 
GLS (%) at peak stress -14.8 ± 3.5 -17.0 ± 4.4 0.008 
 GLS (%) -0.13 ± 2.85 0.36 ± 4.70 0.559 
No. LS seg < -12% at rest 4.9 ± 3.0 3.4 ± 2.5 0.847 
No. LS seg < -12% at peak stress 4.9 ± 3.8 4.0 ± 3.1 0.126 
No. LS seg < -12% 0.00 ± 2.84 -0.60 ± 2.85 0.479 
Positive results  according to WMSI (n/%) 9/25 14/20.3 0.580 
Positive results according to GLS% (n/%) 14/44.4 26/37.7 0.520 
WMSI = wall motion score index;  = change from rest to maximal dose of stressor; GLS = 
global longitudinal strain; LG=longitudinal strain. 
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There was statistically significant correlation 
between presence of DM and decrease of E/A ratio (r 
= -0.278; p = 0.004), shortening of DT (r = -0.332; p = 
0.001) and worsening of GLS% (r = 0.245; p = 0.012) 
at maximal stress, while such correlation didn’t 
appeared regarding stress WMSI. After SE coronary 
angiography was done in 61 patients. Diabetic patient 
in comparison to those without had with borderline 
significance more new and/or worsening CAD (44.8% 
vs. 21.9%; p = 0.057; respectively), especially 
multivessel disease (34.5% vs. 12.5%; p = 0.044; 
respectively) as well as significantly greater Syntax 
score (8.0 vs. 2.5; p = 0.010, respectively) and 
insignificantly more frequently presence of coronary 
artery plaque. There was statistically significant 
correlation between presence of DM and 
angiographycaly proven new and/or worsening CAD (r 
= 0.244; p = 0.058), multivessel disease (r = 0.267; p 
= 0.037), Syntax score (r = 0.327; p = 0.010) and 
diseased Cx coronary artery (r = 0.306; p = 0.016). In 
addition presence of new and/or worsening CAD was 
significantly correlated with WMSI at maximal stress (r 
= 0.386; p = 0.002) and its change during SE (r = -
0.645; p = 0.0001) along with GLS% at maximal 
stress (r = 0.262, p = 0.042) as well as without any 
correlation to functional parameters either of systolic 
or diastolic LV function. 
To determine the independent predictors of 
new and/or worsening CAD among patients who were 
pharmacologically stressed, we performed multiple 
stepwise logistic regression analysis with 
demographic, clinical and echocardiographic 
covariates that showed significant relation to it. The 
results that were adjusted for age and gender, 
demonstrated that WMSI at maximal stress (OR = 
375.8; 95% CI 6.2-22649.7; p = 0.005) and presence 
of DM (OR = 3.8; 95%CI 1.078-13.396; p = 0.038) 
appeared as independent predictors of presence of 
new and/or worsening CAD during SE. Positive 
predictive value of the model was 69.2%, while the 
negative was 77%. 
Figure 1 demonstrates the receiver operator 
characteristics curve (ROC) for predictive probability 
from the model which showed an AUC value of 0.777. 
Also, WMSI at maximal stress and the presence of 
DM during pharmacological SE as a model were 
associated with an acceptable sensitivity of 64% and 
higher specificity (1-20) of 80%. 
 
Figure 1: ROC curve for the presence and/or worsening of 
angiographic CAD using WMSI and DM presence during 
pharmacological SE 
Discussion 
Given that the change of systolic LV 
functional data or rather its improvement from rest to 
peak stress was less pronounced in patients with DM, 
as well parameters of diastolic function and its change 
with stress were almost insignificant (slightly increase 
of E/e’ in DM), we could not find the significant 
functional marker in order to make a difference in 
patients with and without DM. Such results mainly 
differ from our expectations taking into account that 
patients with DM were significantly older, had more 
frequently a history of hypertension, significantly more 
new and/or worsening CAD, especially multivessel 
disease and greater Syntax score. Although 
numerous studies highlighted the role of diastolic 
stress as predictor of CAD presence and its prognosis 
[27], [28], [29], [30], [31] as well in diabetic patients 
[32], [33], [34], we could not provide such evidence 
mainly due to small number of patients with DM in our 
study, lack of performed coronary angiography in all 
patients, possible good controlled risk factors as well 
as due to well-known technical factors regarding TDI 
velocity that can only be measured in one dimension 
and is significantly limited by angle dependence which 
produce difficulties in assessment of multiple wall 
segments (especially apical segments), along with 
influence of heart motion and contraction of adjacent 
segments on TDI data during SE, especially during 
dobutamine application [35]. Also, we could speculate 
that the results of our study were in line with those of 
Fang et al., [36] who detected the normal response to 
stress in diabetic patients without a significant 
difference with a control group that might be due to 
the early stage of diabetic cardiomyopathy. 
Our study showed that visual wall motion 
analysis expressed as WMSI in comparison to 
longitudinal strain assessed using speckle tracking 
(GLS%) didn’t make a difference in SE outcome 
regarding DM presence. WMSI was almost 
unchanged at maximal stress in diabetic patients, and 
paradоxically showed even slight increment in 
patients without DM. However, GLS% showed 
significant worsening at maximal stress in diabetic 
patients which was significantly different to those 
without DM who showed slight improvement. 
Presence of DM was significantly correlated with 
worsening of GLS% at maximal stress, while such 
correlation didn’t appear regarding stress WMSI. 
Given that WMSI and GLS% at maximal stress were 
significantly correlated to new and/or worsening CAD, 
we were expected that two of them would appear as 
its predictors, but regression analysis revealed that 
only WMSI at maximal stress and DM appeared as 
independent predictors of presence of new and/or 
worsening CAD during SE providing sensitivity of the 
model of 64% and specificity of 80%.  
Since Voight et al., [37] demonstrated that 
strain rate analysis during SE provides objective 
evidence of ischemia, the interest of using quantitative 
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assessment of LV systolic function by 2D speckle 
tracking during SE gained interest because it removes 
the subjective nature of visual assessment by wall 
motion analysis (WMA) in detecting CAD. Hence, a 
number of studies have shown that imaging GLS% 
was as good as [38], [39] or even superior [37], [40] 
[41]
 
to conventional echocardiography, subsequently 
lot of them concluding that GLS% provides 
incremental diagnostic accuracy in combination with 
expert WMA [42] in detecting CAD. Our results were 
partly in line with such conclusions; however only 
WMSI appeared as independent predictor of CAD 
which was consistent with the results of dobutamine 
SE study of Celutkiene et al., [43] who stressed that 
none of the single quantitative parameters 
investigated was able to identify significant CAD with 
a comparable diagnostic accuracy vs visual 
assessment using WMA. Also, Nagi et al., [44] fail 
clearly to demonstrate the diagnostic benefit of strain 
analysis over expert WMA alone during contrast-
enhanced SE.  
Given that in diabetic patients risk 
stratification is a major objective considering their 
increased risk for CAD and its’ major cardiovascular 
events, several well-known studies published their 
results that revealed prognostic ability of SE in 
diabetic patients on the basis of conventional WMA 
[45], [16], [18], [44], [33], [34]. Thus, the degree of 
worsening WMSI during SE, especially its’ multivessel 
distribution correlated with the extent of CAD which 
was consistent with our study, but more importunately 
with increasing cardiac events, including death in 
subsequent years. In this respect, it should be born in 
mind that data from studies [33], [34] emphasised that 
regardless a negative test result of SE based solely 
on wall motion criteria in diabetic patients it is 
associated with the less benign outcome which is why 
assessment of GLS% using speckle tracking would be 
an advantage. To our knowledge, data concerning LV 
myocardial deformation during SE in patients with DM 
are available only for longitudinal deformations and 
are still limited to very few studies. Although we could 
not confirm GLS% as independent predictor of CAD 
either in diabetic or nondiabetic patients, the value of 
GLS% at maximal stress appeared as significant 
distinctive parameter for DM presence as well as for 
more extensive CAD which is consistent with the 
study of Wierzbowska-Drabik et al., [45] who found 
more impaired GLS% in patients with DM and CAD at 
rest as well as at maximal SE in comparison to their 
counterparts with CAD but without DM, hence they 
concluded that coexisting CAD and DM had 
synergistic detrimental effect on myocardial strain. 
Furthermore, Philouze et al., [46] confirmed in their 
study that dobutamine SE unmasks functional 
alterations expressed by myocardial mechanics in 
patients with DM that could be barely detectable at 
rest mainly in asymptomatic patients with 
uncomplicated DM.  
The main limitation of our study was a 
relatively small number of patients, especially with 
DM. Patients with DM were older, with higher BMI, 
more frequent history of hypertension and previous 
CAD, which might influence the obtained longitudinal 
strain data. There was no assessment of the influence 
of metabolic control and therapeutic interventions in 
diabetic patients. Coronary angiography was not 
available in all patients, but this is in line with clinical 
guidelines, which do not recommend invasive testing 
in asymptomatic patients. Aiming to good spatial 
resolution and image quality for satisfactory speckle-
tracking during SE, we included in the study and 
analysed only individuals with good acoustic windows.  
The additional long-term analysis of the 
prognostic significance of reduced GLS% at rest and 
stress in patients with DM may potentially increase the 
clinical utility of our observations. 
In conclusion, although wall motion score 
index (WMSI) was insignificantly higher and GLS% 
was worse in diabetic patients at rest, it has been 
shown that the WMSI was almost unchanged during 
stress in both groups of patients, whereas in diabetic 
patients GLS% showed significant worsening at 
maximal stress which. However, besides assessment 
of GLS% appeared superior to qualitative analysis 
expressed by WMSI in making difference regarding 
DM presence, regression analysis revealed that only 
WMSI at maximal stress and DM appeared as 
independent predictors of presence of new and/or 
worsening CAD during SE which lead to conclusion of 
usefulness of using qualitative and/or quantitative 
parameters in detection of CAD in patients with DM 
during stress echocardiography. 
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